Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the Allegro Phase 2b/3 Study

The post-hoc analysis of the ALLEGRO Phase 2b/3 study assessed the long-term efficacy of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in patients aged 12 years and older with alopecia areata and significant scalp hair loss. The study demonstrated that patients who showed a clinical response at Week 24 continued to experience sustained regrowth of scalp, eyebrow, and eyelash hair through Week 48. The treatment groups receiving 50 mg and 30 mg of ritlecitinib, with or without a 200 mg loading dose, showed significant improvements compared to the placebo group, as measured by the Severity of Alopecia Tool (SALT) score. This suggests that ritlecitinib is effective in maintaining hair regrowth in patients with alopecia areata over an extended period.